ARTHUR-D-LITTLE
23.9.2020 10:02:14 CEST | Business Wire | Press release
Following the completion of its ninth Partners’ and Shareholders’ Meeting since becoming a private partnership again in 2011, Arthur D. Little (ADL) today announces the new members of its Board of Directors. The Shareholders’ Meeting also re-elected Ignacio García Alves to serve a new tenure of three years as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005336/en/
The results of the 2020 digital elections for the Board of Directors, with each member to serve a tenure of three years, were as follows:
- Ignacio García Alves (Chairman)
- Rodolfo Guzman
- Yusuke Harada
- Thomas Kuruvilla
- Bernd Schreiber
- Ulrica Sehlstedt
- Nick White.
Held this year as a digital event that included over 100 participants, the Partners’ and Shareholders’ Meeting was an opportunity to celebrate the company’s ongoing success and resilience in the face of an exceptionally challenging year 2020 for the world.
Over the past five years, ADL has doubled in size, expanding its already-global geographic scope with 15 new offices, and adding 19 newly promoted and newly recruited Partners just this year. While pursuing a dynamic, sustainable and profitable growth path, the company has continuously transformed itself. ADL plans to accelerate its development, with substantial investments in people, new leading-edge offerings and digital, plus an increased focus on its unique “open consulting” approach, with the company having been widely recognized for its ability to combine a network of global experts and partner firms, with its own internal strengths.
Ignacio García Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I am very thankful for this renewed expression of confidence, and I am determined to continue the extraordinary development of Arthur D. Little during this new mandate. I would also like to congratulate all new Board members as they take up their roles. I am confident they will be a great support and a vital driving force in aggressively and sustainably developing our company.
“Since our management buyout, we have made continuous and impressive progress, not to mention the strong resilience we have demonstrated during the COVID-19 crisis. I am truly inspired by the sheer energy and winning spirit of our teams. We are now entering a new chapter, and have ambitious plans to invest in the future by building on recent acquisitions (Presans and Cutter Consortium) and driving value through innovative offerings.
“Our commitment remains unchanged: we are here to help our clients, and the communities they serve, overcome today’s most pressing challenges and seize tomorrow’s most promising opportunities.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom